Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim was to investigate the association between pretreatment vitamin D level and response to NAC and subsequent survival outcomes in BC patients.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Given the inherent heterogeneity cross included studies, we performed meta-analysis using a random-effects model with the DerSimonian and Laird method to calculate pooled odds or hazard ratios and their 95% CIs.

Source: Methods.

Publisher article type: review-article

Source: Publisher publication metadata.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies

Review / evidence synthesis · International Journal of Surgery (London, England) · 2024

Original publication title

Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies

Chi Shu; Qian Yang; Jun Huang; Xuan Xie; Hong Li; Hong Wu; Xin Wang; Xin Chen; Yuping Xie; Yanhong Zhou; Yazhou He; Chuan Xu

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our study suggested an association between pretreatment vitamin D deficiency and reduced response to NAC in BC patients, although causality could not be inferred from current evidence with observational design. Therefore, active surveillance on vitamin D level as a biomarker before and during NAC were warranted for BC patients. However, as a safe intervention at a low cost, the causal effect of vitamin D supplementation to improve treatment response could only be proved by future RCTs. Also, our meta-analysis supports a compelling need for future prospective studies with larger sample sizes and well-designed subgroups to strengthen current evidence.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Highlights

  • Pretreatment vitamin D deficiency was associated with 50% increased odds of non-pCR to neoadjuvant chemotherapy in breast cancer patients.

  • Combining estimates from studies using varied criteria for pathological response, lower vitamin D level was also associated with inferior overall response, and potential worse event-free survival.

  • Our findings laid the foundation for future prospective investigations and randomized controlled trials exploring the effects of vitamin D supplementation on improving neoadjuvant chemotherapy response.

Breast cancer (BC) is the most prevalent female malignancy and the fifth leading cause of cancer-related deaths worldwide1. In recent years, neoadjuvant chemotherapy (NAC) has become a standard care for locally advanced BC, in pursuit of an increased breast conservation rate by reducing tumor size2Not reported4. Response to NAC has been robustly linked to higher R0 resection rate and favorable subsequent survival outcomes5,6. However, tumor heterogeneity and variations in patient characteristics impose major challenges in predicting patients’ response to NAC7Not reported9.

Identifying early predictors of response to NAC has important clinical implications in informing treatment efficacy and, therefore, improving prognosis.

Vitamin D is an essential nutrient that plays key roles in a wide spectrum of biological processes. In particular, the antitumor effect of vitamin D has been increasingly recognized, including regulating proliferation, differentiation, apoptosis, angiogenesis, invasion, and metastasis of tumor cells10Not reported12. Preclinical studies have indicated that vitamin D could enhance the efficacy of BC chemotherapy by synergizing or amplifying the cytotoxic activity of antineoplastic agents, such as anthracyclines and taxanes13Not reported15. Specifically, it acts on the transporter to regulate the distribution of the drug in the body, thereby increasing the concentration of the drug in cancer cells16.

Adding vitamin D to paclitaxel could reduce the expression of chemo-resistance marker genes such as multidrug resistance complex 117. Evidence also reported that vitamin D deficiency was associated with a higher risk of side effects such as chemotherapy-induced peripheral neuropathy18. These findings shed light upon the possible role of vitamin D in augmenting the NAC effectiveness within a limited timeframe of a neoadjuvant setting.

Whilst aforementioned biological evidence supported a possible beneficial effect of vitamin D on response to NAC for BC patients, findings of population-level investigations in the association between pretreatment circulating vitamin D and pathological response to NAC remained inconclusive, which might be attributed to the relatively small sample sizes for single clinical investigations regarding NAC for BC patients. In addition, there has been a dearth of a comprehensive review on these evidence despite the potential clinical relevance. We therefore set out to systematically review published evidence and to estimate the association between pretreatment plasma vitamin D level and response to NAC in BC patients with a markedly improved statistical power by performing a meta-analysis.

Source: Introduction Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Study design and search strategies

We searched the Medline, Embase, Cochrane Library, and Web of Science databases and clinical trial registries from inception to 8 October 2024, using combined keywords including ‘breast cancer’ AND (‘vitamin D’ OR ‘25-hydroxyvitamin D’) AND ‘neoadjuvant’. We described the search strategies in detail in the Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The references of relevant articles were manually screened to identify additional eligible studies. Also, the investigators of relevant conference abstracts were traced separately to identify any subsequent potential publications.

This work has been reported in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)19 checklist presented in Supplemental Digital Content 2, http://links.lww.com/JS9/D557 and flow diagram in Supplemental Digital Content 3, http://links.lww.com/JS9/D558 and Assessing the methodological quality of systematic reviews (AMSTAR)-2 guidelines20 (Supplemental Digital Content 4, http://links.lww.com/JS9/D559). The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO, CRD42024532891).

Inclusion and exclusion criteria

Eligible studies were expected to meet the following inclusion criteria: 1) studies focusing on females with histologically confirmed BC; 2) investigations with sample sizes no less than 30; 3) studies that assayed pretreatment circulating vitamin D level at BC diagnosis as the primary exposure; 4) studies that adopted measures for NAC response, such as pCR, or long-term (≥12 months) survival outcomes for particular events, for example, tumor recurrence or death from BC after NAC as the outcomes; 5) investigations with study designs including clinical trials, prospective or retrospective cohort studies, and case: control studies.

Studies were excluded if they were published as conference abstracts, comments, case reports, letters, or editorials. During the screening process, two reviewers (C.S. and Q.Y.) independently screened titles and abstracts, with disagreements resolved by consensus or consultation with a third reviewer (Y.H.). We documented the source of included patients in each study, namely the patient database, registry, or study cohort, along with the time-span of patient enrollment to ascertain whether there were overlapping patients included by other eligible studies. Where the name of the data source was not provided, we noted the hospital or institute of patient enrollment instead.

If multiple studies included patients from the same data source or institution within an overlapped time span, only the latest publication was included.

Data extraction and quality assessment

Data items regarding basic characteristics were extracted from each eligible study by two independent reviewers (C.S. and Q.Y.), including the first author, publication year, data source, country, study design, molecular subtypes, clinical tumor stage, vitamin D assessment measure, pretreatment vitamin D level, vitamin D deficiency cut-off value, outcome measures, and sample sizes. The details of data extraction items are presented in the Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). We also documented effect estimates reported by each study including odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% CI (or event numbers where effect estimates could be derived).

HRs with 95% CIs were not obtained from the survival curves.

We evaluated the methodological quality of the included studies using the Newcastle: Ottawa Scale (NOS)21,22. The scoring criteria are presented in the Supplemental Method 1 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). Studies with the NOS scores no less than 7 were deemed high quality. Any discrepancies were solved by discussion with a senior clinician and epidemiologist (Y.H. and C.X.).

Outcome definition

We employed the pCR as the primary outcome, which was defined as the absence of invasive tumor cellularity in the resected breast tumor specimen and axillary lymph nodes after NAC (residual in situ cancer without invasive cancer was considered to have a pCR23). Previous evidence has established robust associations between achieving pCR and improved long-term survival outcomes in BC5,6; and subsequently pCR has been officially listed as a recommended surrogate outcome by the Food and Drug Administration (FDA) and European Medicines Agency (EMA)24,25.

We also defined an overall pathological response to NAC by combining treatment responses using a combined criteria, that is patients showing responses determined by achieving pCR or response in any of other criteria including residual cancer burden (RCB)26 score (RCB ≤1 was defined as responders) and Miller-Payne grading (MPG, grade ≥4 was defined as responders)27. The detailed definitions for each outcome are summarized in the Supplemental Method 2 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). As for survival outcomes, an event-free survival (EFS), where events included local recurrence, distant metastasis, or death from cancer, was adopted to evaluate any associations with long-term prognosis.

Statistical analysis

All statistical analysis was conducted using the ‘meta’ package of R statistical software (version 4.1.3; https://www.R-project.org/). We conducted evidence synthesis to estimate the pooled effect estimates of vitamin D deficiency (defined as pretreatment serum vitamin D<20 ng/ml based on the recommendation from Institute of Medicine [IOM]28) on each outcome. The between-study heterogeneity in the reported effect estimates was estimated using the I 2 statistic29. Given the inherent heterogeneity cross included studies, we performed meta-analysis using a random-effects model with the DerSimonian and Laird method to calculate pooled odds or hazard ratios and their 95% CIs.

Forest plots were used to visualize each individual and the pooled effect estimates with their 95% CIs. An OR or HR >1 indicated a detrimental effect of vitamin D deficiency on the odds of response to NAC.

Subgroup analyses were preplanned based on prior evidence that suggested possible varied vitamin D effects across different patient strata, including biological relevance (tumor stage30, molecular subtype31,32), treatment regimen33, patient ethnicity34, and cut-off thresholds of vitamin D level35. We assessed publication bias by visual evaluation of the funnel plot symmetry and by conducting the Egger’s36 tests where a P-value<0.10 indicated the presence of a significant small study effect. Sensitivity analyses were conducted by excluding studies of lower quality (NOS<7) from the meta-analysis.

All statistical tests were 2-sided, with a P-value <0.05 deemed statistically significant.

Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods

Results: Study selection and quality assessment

Our initial literature search yielded 189 citations. After excluding 46 duplicates, 132 studies were removed by reviewing the titles and abstracts based on our inclusion criteria. After that, a total of eleven studies were reviewed in full text5,37Not reported46. Of which, one study was excluded due to a duplicated study population5, one study was excluded for a small sample size (<30)43, three studies were excluded for lacking available outcome data44Not reported46 (details of the flow diagram presented in Fig. 1).

Figure 1

Flowchart of the studies selection process.

Figure image at the original source: open the original paper. This file is not included in this text import.

Six studies with a total of 1291 BC patients were included37Not reported42. All studies were retrospective in design. Agents used in the NAC regimens adopted by these studies included anthracycline-based drugs, taxane, and trastuzumab. All included studies examined serum vitamin D levels prior to NAC. The basic characteristics of eligible studies are presented in Table 1 and the Supplemental Table 3 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556), where all six included studies enrolled patients from independent data sources with no duplicate.

Three studies were assigned with high methodological quality (NOS≥7)37,38,40. The detailed results of the quality assessment are presented in the Supplemental Tables 4 to 6 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The risk of biases for the included studies was likely to occur in aspects of patient selection and comparability across groups (Fig. 2 and Supplemental Fig. 1A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The quality of evidence for included studies (AMSTAR-2) is presented in Supplemental Digital Content 4, http://links.lww.com/JS9/D559.

Table 1

Main characteristic of included studies.

AuthorYearCountryData sourceStudy designMolecular subtypesTumor stageVitamin D assessmentVitamin D deficiency cut-off value, ng/mlOutcomesOR or HR (95% CI)Sample sizes
Clark37 2014AmericaI-SPY1 TrialRHER-2 negativeII: IIIRIA<20 vs. ≥20 or per 1-unit decreasea RCB
EFS
ORa: 1.01 (0.96 to 1.05)
OR: 0.75 (0.14 to 2.19)
HR: 1.30 (0.57 to 2.94)
82
Charehbili38 2016NetherlandsNEOZOTAC TrialRHER-2 negativeII: IIINRPer 1-unit decreasea pCRORa: 1.00 (0.99 to 1.01)169
Kim39 2018KoreaSeverance HospitalRNSI: IIIRIA<20 vs. ≥20pCR
EFS
OR: 1.54 (0.92 to 2.60)
HR: 1.00 (0.46 to 2.17)
374
Viala40 2018America, FranceCancer Center in Montpellier and LowaRNSI: IIIECLIA, MFA<20 vs. ≥20pCR
EFS
OR: 1.64 (1.02 to 2.66)
HR: 1.11 (0.67 to 1.67)
327
Atci41 2021TurkeyIstanbul City HospitalRNSIIIECLIA<20 vs. ≥20MPGOR: 0.63 (0.27 to 1.47)89
Tokunaga42 2022JapanKyushu Cancer CenterRNSI: IIIELISA<20 vs. ≥20pCR
EFS
OR: 1.27 (0.71 to 2.28)
HR: 2.28 (1.12 to 5.03)
250

ECLIA, electrochemiluminescence immunoassay; EFS, event-free survival, including recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS) and time to distant recurrence (TTDR); ELISA, Enzyme linked immunosorbent assay; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; MFA, multiplex flow immunoassay; MPG, Miller-Payne grading (MPG ≥ 4 was defined as responders); NR, not reported; NS, not specified; OR, odds ratio; pCR, pathological complete response (No invasive tumor cell in the resected breast tumor specimen and axillary lymph nodes after neoadjuvant chemotherapy); R, retrospective; RCB, residual cancer burden (RCB ≤ 1 was defined as responders); RIA, radioimmunoassay.

a

Vitamin D as a continuous variable.

Figure 2

Risk of bias plot on pathological complete response (pCR).

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Study selection and quality assessment Source: Study selection and quality assessment Source: Study selection and quality assessment Source: Study selection and quality assessment Source: Study selection and quality assessment

Associations between vitamin D and NAC response

Results: Associations between vitamin D and NAC response

Among the included studies, three included stage I: III tumors and used pCR as the primary outcome to measure the pathological response to NAC. As shown in Fig. 3A, by conducting meta-analysis, we observed a significant association between pretreatment vitamin D deficiency and an increased odd of non-pCR (OR=1.50, 95% CI: 1.11 to 2.03, P=0.008). Of note, effect estimates reported by these three studies showed good consistency where no between-study heterogeneity was detected (I 2=0%). As for overall pathological response (Fig. 3B) with combined measures of pCR, RCB and MPG, five studies were included and the meta-analysis identified a significant association of vitamin D deficiency with inferior response to NAC (OR=1.33, 95% CI: 1.01 to 1.75, P=0.046).

Of note, we observed a moderate level of heterogeneity (I2=15%) for this outcome with a broader definition of response. Visual inspection of the contour-enhanced funnel plot (Supplemental Fig. 2A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) did not identify any evident asymmetry, and the Egger’s test did not find any significant small study effects or publication bias (pCR: P=0.104; overall pathological response: P=0.819).

Figure 3

A Forest plot of the effects of vitamin D deficiency on not achieving pathological complete response (pCR); B Forest plot of the effects of vitamin D deficiency on no overall pathological response; C Forest plot of the effects of vitamin D deficiency on event-free survival (EFS).

Figure image at the original source: open the original paper. This file is not included in this text import.

Four studies reported EFS in BC patients receiving NAC. As shown in the forest plot (Fig. 3C), with mild heterogeneity revealed (I 2=1%), BC patients with pretreatment vitamin D deficiency tended to experience inferior EFS, although the association was not statistically significant (HR=1.27, 95% CI: 0.92 to 1.75, P=0.139). The funnel plot for EFS (Supplemental Fig. 2C of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) was also deemed symmetrical, with an Egger’s test presenting no evidence of small study effects (P=0.585).

Source: Associations between vitamin D and NAC response Source: Associations between vitamin D and NAC response Source: Associations between vitamin D and NAC response

Results: Subgroup and sensitivity analysis

We conducted a subgroup meta-analysis using a random-effects model based on different study characteristics, including molecular subtype (hormone receptor, HR), treatment regimen, patient ethnicity, and clinical tumor stage. Outside meta-analysis on studies including stages I: III patients where pCR was adopted as the primary outcome, we did not find any significant associations between vitamin D deficiency and response to NAC, although all the pooled estimates showed concordant directions of effect that indicated potential harmful roles of vitamin D deficiency on NAC response (vitamin D as a dichotomous variable, with forest plots presented in Fig. 4A: F).

Similar results were also found in terms of overall pathological response (vitamin D as a continuous variable, Supplemental Fig. 3 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556), as well as EFS (regimen, ethnicity, and tumor stage, Supplemental Fig. 4A: D of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Figure 4

Subgroup analysis on the overall pathological response (vitamin D as a dichotomous variable). A Subgroup plot with HR-positive; B Subgroup plot with HR negative; C Subgroup plot with Chemotherapy including trastuzumab; D Subgroup plot with Asian; E Subgroup plot with European; F subgroup plot with stages I: III; HR-positive: Either estrogen receptor (ER) or progesterone receptor (PR) is positive; HR negative: Both estrogen and progesterone receptors are negative.

Figure image at the original source: open the original paper. This file is not included in this text import.

We conducted sensitivity analysis on response to NAC (Supplemental Fig. 5A of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) and EFS (Supplemental Fig. 5B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) outcomes by including only studies with high methodological quality (NOS≥7), and the direction of effects remained consistent (response: OR=1.46, 95% CI: 0.85 to 2.52, P=0.170; EFS: OR=1.27, 95% CI: 0.92 to 1.75, P=0.139). In addition, two studies analyzed the association using vitamin D level of a continuous scale37,38, our meta-analysis failed to observe a significant association between lower vitamin D (per 1 unit) and response to NAC (OR=1.00, 95% CI: 0.99 to 1.01, P=0.924, Supplemental Fig. 6 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Source: Subgroup and sensitivity analysis Source: Subgroup and sensitivity analysis Source: Subgroup and sensitivity analysis

Discussion: Strengths and limitations of the study

We have performed, to our best knowledge, the first systematic review and meta-analysis on the association between pretreatment vitamin D and response to NAC in BC patients. However, there were several limitations that should be noted for current evidence. Firstly, although our meta-analysis has provided pooled effect estimates with much improved statistical power, relatively small sample sizes, especially for specific subgroups, could limit the credibility of our findings. Given the unavailable individual-level data, we were unable to adjust the possible confounders such as comorbidities and lifestyles (e.g. obesity and physical activity), which were associated with vitamin D level and could influence response to NAC.

Moreover, there has been a lack of data for patients of particular molecular subtypes such as triple-negative BC. Secondly, the retrospective nature of included studies incurred a risk of biases, and the observed association could not be interpreted as causality. Our study calls for more prospective studies with larger sample sizes to further validate the association. Thirdly, the included studies used the same threshold to dichotomize vitamin D, although the measured level could vary across diverse populations and different measuring techniques, which remained to be further investigated with more granular data accumulated in the future.

Fourthly, although the funnel plots and Egger’s test did not identify significant biases from small study effects, the statistical tests were underpowered due to the small number of included studies (n<10) and the results should be interpreted with caution. Finally, due to limited data, current evidence was unable to address the possible dose-response effect of vitamin D on NAC response. As such, future efforts are imperative to conduct large-scale prospective cohort studies with well-defined subgroups of various molecular subtypes to reassess this association.

Source: Strengths and limitations of the study

Clinical implications and future directions

Discussion: Clinical implications and future directions

Vitamin D deficiency is highly prevalent worldwide and persists as a potential shared risk factor for many conditions including cancer, posing a major threat to human health63. BC patients are more susceptible to vitamin D deficiency in comparison to the general population64,65. Moreover, a significant decrease of the vitamin D level has been widely observed after the completion of NAC in BC patients66,67. Previous evidence has observed an adverse impact of lower plasma vitamin D level on survival outcomes of BC patients, on top of which our study provided further insights that vitamin D could potentially sensitize patients to NAC.

Our meta-analysis of retrospective cohorts calls for more prospective studies to investigate the potential causality between vitamin D and response to NAC. On the basis of a robust association, advanced approaches such as mendelian randomization could be performed to explore the potential causality between vitamin D level and clinical outcomes in BC patients, and randomized controlled trials (RCTs) that investigate the effects of vitamin D supplementation with varied doses and time schedules on improving response to NAC in BC patients are also expected in the future.

Also, as circulating vitamin D can be readily modified at a low cost, our findings highlighted the possibility of improving response to NAC for BC patients via vitamin D supplementation and laid the groundwork for future well-designed clinical investigations exploring varied doses of vitamin D supplementation for BC patients receiving NAC. Given the limited sample size of current studies68, whether intense pretreatment vitamin D supplementation could compensate for the adverse impact on response to NAC or whether it would be too late still needs to be verified by future population-based prospective studies.

Source: Clinical implications and future directions Source: Clinical implications and future directions

Source of funding

This work was supported by the National Key Research and Development Program of China (grant no. 2023YFC3402100), the National Natural Science Foundation of China (grant no. 92259102 and 82103918), the Natural Science Foundation of Sichuan Province (grant no. 2024NSFSC0057 and 2025NSFSC0554).

Source: Source of funding

Results

Study selection and quality assessment

Our initial literature search yielded 189 citations. After excluding 46 duplicates, 132 studies were removed by reviewing the titles and abstracts based on our inclusion criteria. After that, a total of eleven studies were reviewed in full text5,37Not reported46. Of which, one study was excluded due to a duplicated study population5, one study was excluded for a small sample size (<30)43, three studies were excluded for lacking available outcome data44Not reported46 (details of the flow diagram presented in Fig. 1).

Figure 1

Flowchart of the studies selection process.

Figure image at the original source: open the original paper. This file is not included in this text import.

Six studies with a total of 1291 BC patients were included37Not reported42. All studies were retrospective in design. Agents used in the NAC regimens adopted by these studies included anthracycline-based drugs, taxane, and trastuzumab. All included studies examined serum vitamin D levels prior to NAC. The basic characteristics of eligible studies are presented in Table 1 and the Supplemental Table 3 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556), where all six included studies enrolled patients from independent data sources with no duplicate.

Three studies were assigned with high methodological quality (NOS≥7)37,38,40. The detailed results of the quality assessment are presented in the Supplemental Tables 4 to 6 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The risk of biases for the included studies was likely to occur in aspects of patient selection and comparability across groups (Fig. 2 and Supplemental Fig. 1A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The quality of evidence for included studies (AMSTAR-2) is presented in Supplemental Digital Content 4, http://links.lww.com/JS9/D559.

Table 1

Main characteristic of included studies.

AuthorYearCountryData sourceStudy designMolecular subtypesTumor stageVitamin D assessmentVitamin D deficiency cut-off value, ng/mlOutcomesOR or HR (95% CI)Sample sizes
Clark37 2014AmericaI-SPY1 TrialRHER-2 negativeII: IIIRIA<20 vs. ≥20 or per 1-unit decreasea RCB
EFS
ORa: 1.01 (0.96 to 1.05)
OR: 0.75 (0.14 to 2.19)
HR: 1.30 (0.57 to 2.94)
82
Charehbili38 2016NetherlandsNEOZOTAC TrialRHER-2 negativeII: IIINRPer 1-unit decreasea pCRORa: 1.00 (0.99 to 1.01)169
Kim39 2018KoreaSeverance HospitalRNSI: IIIRIA<20 vs. ≥20pCR
EFS
OR: 1.54 (0.92 to 2.60)
HR: 1.00 (0.46 to 2.17)
374
Viala40 2018America, FranceCancer Center in Montpellier and LowaRNSI: IIIECLIA, MFA<20 vs. ≥20pCR
EFS
OR: 1.64 (1.02 to 2.66)
HR: 1.11 (0.67 to 1.67)
327
Atci41 2021TurkeyIstanbul City HospitalRNSIIIECLIA<20 vs. ≥20MPGOR: 0.63 (0.27 to 1.47)89
Tokunaga42 2022JapanKyushu Cancer CenterRNSI: IIIELISA<20 vs. ≥20pCR
EFS
OR: 1.27 (0.71 to 2.28)
HR: 2.28 (1.12 to 5.03)
250

ECLIA, electrochemiluminescence immunoassay; EFS, event-free survival, including recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS) and time to distant recurrence (TTDR); ELISA, Enzyme linked immunosorbent assay; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; MFA, multiplex flow immunoassay; MPG, Miller-Payne grading (MPG ≥ 4 was defined as responders); NR, not reported; NS, not specified; OR, odds ratio; pCR, pathological complete response (No invasive tumor cell in the resected breast tumor specimen and axillary lymph nodes after neoadjuvant chemotherapy); R, retrospective; RCB, residual cancer burden (RCB ≤ 1 was defined as responders); RIA, radioimmunoassay.

a

Vitamin D as a continuous variable.

Figure 2

Risk of bias plot on pathological complete response (pCR).

Figure image at the original source: open the original paper. This file is not included in this text import.

Associations between vitamin D and NAC response

Among the included studies, three included stage I: III tumors and used pCR as the primary outcome to measure the pathological response to NAC. As shown in Fig. 3A, by conducting meta-analysis, we observed a significant association between pretreatment vitamin D deficiency and an increased odd of non-pCR (OR=1.50, 95% CI: 1.11 to 2.03, P=0.008). Of note, effect estimates reported by these three studies showed good consistency where no between-study heterogeneity was detected (I 2=0%). As for overall pathological response (Fig. 3B) with combined measures of pCR, RCB and MPG, five studies were included and the meta-analysis identified a significant association of vitamin D deficiency with inferior response to NAC (OR=1.33, 95% CI: 1.01 to 1.75, P=0.046).

Of note, we observed a moderate level of heterogeneity (I2=15%) for this outcome with a broader definition of response. Visual inspection of the contour-enhanced funnel plot (Supplemental Fig. 2A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) did not identify any evident asymmetry, and the Egger’s test did not find any significant small study effects or publication bias (pCR: P=0.104; overall pathological response: P=0.819).

Figure 3

A Forest plot of the effects of vitamin D deficiency on not achieving pathological complete response (pCR); B Forest plot of the effects of vitamin D deficiency on no overall pathological response; C Forest plot of the effects of vitamin D deficiency on event-free survival (EFS).

Figure image at the original source: open the original paper. This file is not included in this text import.

Four studies reported EFS in BC patients receiving NAC. As shown in the forest plot (Fig. 3C), with mild heterogeneity revealed (I 2=1%), BC patients with pretreatment vitamin D deficiency tended to experience inferior EFS, although the association was not statistically significant (HR=1.27, 95% CI: 0.92 to 1.75, P=0.139). The funnel plot for EFS (Supplemental Fig. 2C of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) was also deemed symmetrical, with an Egger’s test presenting no evidence of small study effects (P=0.585).

Subgroup and sensitivity analysis

We conducted a subgroup meta-analysis using a random-effects model based on different study characteristics, including molecular subtype (hormone receptor, HR), treatment regimen, patient ethnicity, and clinical tumor stage. Outside meta-analysis on studies including stages I: III patients where pCR was adopted as the primary outcome, we did not find any significant associations between vitamin D deficiency and response to NAC, although all the pooled estimates showed concordant directions of effect that indicated potential harmful roles of vitamin D deficiency on NAC response (vitamin D as a dichotomous variable, with forest plots presented in Fig. 4A: F).

Similar results were also found in terms of overall pathological response (vitamin D as a continuous variable, Supplemental Fig. 3 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556), as well as EFS (regimen, ethnicity, and tumor stage, Supplemental Fig. 4A: D of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Figure 4

Subgroup analysis on the overall pathological response (vitamin D as a dichotomous variable). A Subgroup plot with HR-positive; B Subgroup plot with HR negative; C Subgroup plot with Chemotherapy including trastuzumab; D Subgroup plot with Asian; E Subgroup plot with European; F subgroup plot with stages I: III; HR-positive: Either estrogen receptor (ER) or progesterone receptor (PR) is positive; HR negative: Both estrogen and progesterone receptors are negative.

Figure image at the original source: open the original paper. This file is not included in this text import.

We conducted sensitivity analysis on response to NAC (Supplemental Fig. 5A of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) and EFS (Supplemental Fig. 5B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) outcomes by including only studies with high methodological quality (NOS≥7), and the direction of effects remained consistent (response: OR=1.46, 95% CI: 0.85 to 2.52, P=0.170; EFS: OR=1.27, 95% CI: 0.92 to 1.75, P=0.139). In addition, two studies analyzed the association using vitamin D level of a continuous scale37,38, our meta-analysis failed to observe a significant association between lower vitamin D (per 1 unit) and response to NAC (OR=1.00, 95% CI: 0.99 to 1.01, P=0.924, Supplemental Fig. 6 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Source: Results Source: Results Source: Results

Conclusion

Our study suggested an association between pretreatment vitamin D deficiency and reduced response to NAC in BC patients, although causality could not be inferred from current evidence with observational design. Therefore, active surveillance on vitamin D level as a biomarker before and during NAC were warranted for BC patients. However, as a safe intervention at a low cost, the causal effect of vitamin D supplementation to improve treatment response could only be proved by future RCTs. Also, our meta-analysis supports a compelling need for future prospective studies with larger sample sizes and well-designed subgroups to strengthen current evidence.

Source: Conclusion
Authors’ abstract

Background:

Biological evidence has revealed antitumor effect of vitamin D, but whether it could predict the response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients remains inconclusive. The aim was to investigate the association between pretreatment vitamin D level and response to NAC and subsequent survival outcomes in BC patients.

Materials and methods:

The authors systematically searched the Medline, Embase, Cochrane Library, and Web of Science databases and clinical trial registries to identify relevant articles from inception to 8 October 2024. Eligible studies investigating the associations between pretreatment plasma vitamin D and response to NAC in BC patients were selected according to the predefined criteria, with the study characteristics extracted by two reviewers. The primary outcome was pathological complete response (pCR), while overall pathological response and event-free survival (EFS) were adopted as secondary outcomes.

Summary effect estimates of odds ratios (ORs) or hazard ratios (HRs) with 95% CIs were pooled using a random-effects model. Subgroup and sensitivity analyses were performed based on study characteristics and methodological quality.

Results:

Six retrospective cohort studies involving 1291 BC patients were included. The authors observed a significant association between pretreatment vitamin D deficiency and 50% increased odds of non-pCR after NAC (OR=1.50, 95% CI: 1.11 to 2.03, P=0.008) with no heterogeneity (I 2=0%). The authors also identified a significant association of vitamin D with the overall pathological response (OR=1.33, 95% CI: 1.01 to 1.75, P=0.046). A similar association with EFS (HR=1.27, 95% CI: 0.92 to 1.75, P=0.139) was also noted although the effect estimate was not statistically significant.

Sensitivity analyses based on methodological quality showed consistent findings.

Conclusion:

Pretreatment vitamin D deficiency is associated with an inferior response to NAC in BC patients. Our meta-analysis advocates further prospective studies with large sample sizes before vitamin D supplementation could be administered to improve NAC response and subsequent prognosis of BC patients.

Read the full paper

Introduction

Highlights

  • Pretreatment vitamin D deficiency was associated with 50% increased odds of non-pCR to neoadjuvant chemotherapy in breast cancer patients.

  • Combining estimates from studies using varied criteria for pathological response, lower vitamin D level was also associated with inferior overall response, and potential worse event-free survival.

  • Our findings laid the foundation for future prospective investigations and randomized controlled trials exploring the effects of vitamin D supplementation on improving neoadjuvant chemotherapy response.

Breast cancer (BC) is the most prevalent female malignancy and the fifth leading cause of cancer-related deaths worldwide1. In recent years, neoadjuvant chemotherapy (NAC) has become a standard care for locally advanced BC, in pursuit of an increased breast conservation rate by reducing tumor size2Not reported4. Response to NAC has been robustly linked to higher R0 resection rate and favorable subsequent survival outcomes5,6. However, tumor heterogeneity and variations in patient characteristics impose major challenges in predicting patients’ response to NAC7Not reported9.

Identifying early predictors of response to NAC has important clinical implications in informing treatment efficacy and, therefore, improving prognosis.

Vitamin D is an essential nutrient that plays key roles in a wide spectrum of biological processes. In particular, the antitumor effect of vitamin D has been increasingly recognized, including regulating proliferation, differentiation, apoptosis, angiogenesis, invasion, and metastasis of tumor cells10Not reported12. Preclinical studies have indicated that vitamin D could enhance the efficacy of BC chemotherapy by synergizing or amplifying the cytotoxic activity of antineoplastic agents, such as anthracyclines and taxanes13Not reported15. Specifically, it acts on the transporter to regulate the distribution of the drug in the body, thereby increasing the concentration of the drug in cancer cells16.

Adding vitamin D to paclitaxel could reduce the expression of chemo-resistance marker genes such as multidrug resistance complex 117. Evidence also reported that vitamin D deficiency was associated with a higher risk of side effects such as chemotherapy-induced peripheral neuropathy18. These findings shed light upon the possible role of vitamin D in augmenting the NAC effectiveness within a limited timeframe of a neoadjuvant setting.

Whilst aforementioned biological evidence supported a possible beneficial effect of vitamin D on response to NAC for BC patients, findings of population-level investigations in the association between pretreatment circulating vitamin D and pathological response to NAC remained inconclusive, which might be attributed to the relatively small sample sizes for single clinical investigations regarding NAC for BC patients. In addition, there has been a dearth of a comprehensive review on these evidence despite the potential clinical relevance. We therefore set out to systematically review published evidence and to estimate the association between pretreatment plasma vitamin D level and response to NAC in BC patients with a markedly improved statistical power by performing a meta-analysis.

Materials and methods

Study design and search strategies

We searched the Medline, Embase, Cochrane Library, and Web of Science databases and clinical trial registries from inception to 8 October 2024, using combined keywords including ‘breast cancer’ AND (‘vitamin D’ OR ‘25-hydroxyvitamin D’) AND ‘neoadjuvant’. We described the search strategies in detail in the Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The references of relevant articles were manually screened to identify additional eligible studies. Also, the investigators of relevant conference abstracts were traced separately to identify any subsequent potential publications.

This work has been reported in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)19 checklist presented in Supplemental Digital Content 2, http://links.lww.com/JS9/D557 and flow diagram in Supplemental Digital Content 3, http://links.lww.com/JS9/D558 and Assessing the methodological quality of systematic reviews (AMSTAR)-2 guidelines20 (Supplemental Digital Content 4, http://links.lww.com/JS9/D559). The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO, CRD42024532891).

Inclusion and exclusion criteria

Eligible studies were expected to meet the following inclusion criteria: 1) studies focusing on females with histologically confirmed BC; 2) investigations with sample sizes no less than 30; 3) studies that assayed pretreatment circulating vitamin D level at BC diagnosis as the primary exposure; 4) studies that adopted measures for NAC response, such as pCR, or long-term (≥12 months) survival outcomes for particular events, for example, tumor recurrence or death from BC after NAC as the outcomes; 5) investigations with study designs including clinical trials, prospective or retrospective cohort studies, and case: control studies.

Studies were excluded if they were published as conference abstracts, comments, case reports, letters, or editorials. During the screening process, two reviewers (C.S. and Q.Y.) independently screened titles and abstracts, with disagreements resolved by consensus or consultation with a third reviewer (Y.H.). We documented the source of included patients in each study, namely the patient database, registry, or study cohort, along with the time-span of patient enrollment to ascertain whether there were overlapping patients included by other eligible studies. Where the name of the data source was not provided, we noted the hospital or institute of patient enrollment instead.

If multiple studies included patients from the same data source or institution within an overlapped time span, only the latest publication was included.

Data extraction and quality assessment

Data items regarding basic characteristics were extracted from each eligible study by two independent reviewers (C.S. and Q.Y.), including the first author, publication year, data source, country, study design, molecular subtypes, clinical tumor stage, vitamin D assessment measure, pretreatment vitamin D level, vitamin D deficiency cut-off value, outcome measures, and sample sizes. The details of data extraction items are presented in the Supplemental Table 2 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). We also documented effect estimates reported by each study including odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% CI (or event numbers where effect estimates could be derived).

HRs with 95% CIs were not obtained from the survival curves.

We evaluated the methodological quality of the included studies using the Newcastle: Ottawa Scale (NOS)21,22. The scoring criteria are presented in the Supplemental Method 1 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). Studies with the NOS scores no less than 7 were deemed high quality. Any discrepancies were solved by discussion with a senior clinician and epidemiologist (Y.H. and C.X.).

Outcome definition

We employed the pCR as the primary outcome, which was defined as the absence of invasive tumor cellularity in the resected breast tumor specimen and axillary lymph nodes after NAC (residual in situ cancer without invasive cancer was considered to have a pCR23). Previous evidence has established robust associations between achieving pCR and improved long-term survival outcomes in BC5,6; and subsequently pCR has been officially listed as a recommended surrogate outcome by the Food and Drug Administration (FDA) and European Medicines Agency (EMA)24,25.

We also defined an overall pathological response to NAC by combining treatment responses using a combined criteria, that is patients showing responses determined by achieving pCR or response in any of other criteria including residual cancer burden (RCB)26 score (RCB ≤1 was defined as responders) and Miller-Payne grading (MPG, grade ≥4 was defined as responders)27. The detailed definitions for each outcome are summarized in the Supplemental Method 2 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). As for survival outcomes, an event-free survival (EFS), where events included local recurrence, distant metastasis, or death from cancer, was adopted to evaluate any associations with long-term prognosis.

Statistical analysis

All statistical analysis was conducted using the ‘meta’ package of R statistical software (version 4.1.3; https://www.R-project.org/). We conducted evidence synthesis to estimate the pooled effect estimates of vitamin D deficiency (defined as pretreatment serum vitamin D<20 ng/ml based on the recommendation from Institute of Medicine [IOM]28) on each outcome. The between-study heterogeneity in the reported effect estimates was estimated using the I 2 statistic29. Given the inherent heterogeneity cross included studies, we performed meta-analysis using a random-effects model with the DerSimonian and Laird method to calculate pooled odds or hazard ratios and their 95% CIs.

Forest plots were used to visualize each individual and the pooled effect estimates with their 95% CIs. An OR or HR >1 indicated a detrimental effect of vitamin D deficiency on the odds of response to NAC.

Subgroup analyses were preplanned based on prior evidence that suggested possible varied vitamin D effects across different patient strata, including biological relevance (tumor stage30, molecular subtype31,32), treatment regimen33, patient ethnicity34, and cut-off thresholds of vitamin D level35. We assessed publication bias by visual evaluation of the funnel plot symmetry and by conducting the Egger’s36 tests where a P-value<0.10 indicated the presence of a significant small study effect. Sensitivity analyses were conducted by excluding studies of lower quality (NOS<7) from the meta-analysis.

All statistical tests were 2-sided, with a P-value <0.05 deemed statistically significant.

Results

Study selection and quality assessment

Our initial literature search yielded 189 citations. After excluding 46 duplicates, 132 studies were removed by reviewing the titles and abstracts based on our inclusion criteria. After that, a total of eleven studies were reviewed in full text5,37Not reported46. Of which, one study was excluded due to a duplicated study population5, one study was excluded for a small sample size (<30)43, three studies were excluded for lacking available outcome data44Not reported46 (details of the flow diagram presented in Fig. 1).

Figure 1

Flowchart of the studies selection process.

Figure image at the original source: open the original paper. This file is not included in this text import.

Six studies with a total of 1291 BC patients were included37Not reported42. All studies were retrospective in design. Agents used in the NAC regimens adopted by these studies included anthracycline-based drugs, taxane, and trastuzumab. All included studies examined serum vitamin D levels prior to NAC. The basic characteristics of eligible studies are presented in Table 1 and the Supplemental Table 3 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556), where all six included studies enrolled patients from independent data sources with no duplicate.

Three studies were assigned with high methodological quality (NOS≥7)37,38,40. The detailed results of the quality assessment are presented in the Supplemental Tables 4 to 6 (Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The risk of biases for the included studies was likely to occur in aspects of patient selection and comparability across groups (Fig. 2 and Supplemental Fig. 1A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556). The quality of evidence for included studies (AMSTAR-2) is presented in Supplemental Digital Content 4, http://links.lww.com/JS9/D559.

Table 1

Main characteristic of included studies.

AuthorYearCountryData sourceStudy designMolecular subtypesTumor stageVitamin D assessmentVitamin D deficiency cut-off value, ng/mlOutcomesOR or HR (95% CI)Sample sizes
Clark37 2014AmericaI-SPY1 TrialRHER-2 negativeII: IIIRIA<20 vs. ≥20 or per 1-unit decreasea RCB
EFS
ORa: 1.01 (0.96 to 1.05)
OR: 0.75 (0.14 to 2.19)
HR: 1.30 (0.57 to 2.94)
82
Charehbili38 2016NetherlandsNEOZOTAC TrialRHER-2 negativeII: IIINRPer 1-unit decreasea pCRORa: 1.00 (0.99 to 1.01)169
Kim39 2018KoreaSeverance HospitalRNSI: IIIRIA<20 vs. ≥20pCR
EFS
OR: 1.54 (0.92 to 2.60)
HR: 1.00 (0.46 to 2.17)
374
Viala40 2018America, FranceCancer Center in Montpellier and LowaRNSI: IIIECLIA, MFA<20 vs. ≥20pCR
EFS
OR: 1.64 (1.02 to 2.66)
HR: 1.11 (0.67 to 1.67)
327
Atci41 2021TurkeyIstanbul City HospitalRNSIIIECLIA<20 vs. ≥20MPGOR: 0.63 (0.27 to 1.47)89
Tokunaga42 2022JapanKyushu Cancer CenterRNSI: IIIELISA<20 vs. ≥20pCR
EFS
OR: 1.27 (0.71 to 2.28)
HR: 2.28 (1.12 to 5.03)
250

ECLIA, electrochemiluminescence immunoassay; EFS, event-free survival, including recurrence-free survival (RFS), disease-free survival (DFS), progression-free survival (PFS) and time to distant recurrence (TTDR); ELISA, Enzyme linked immunosorbent assay; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; MFA, multiplex flow immunoassay; MPG, Miller-Payne grading (MPG ≥ 4 was defined as responders); NR, not reported; NS, not specified; OR, odds ratio; pCR, pathological complete response (No invasive tumor cell in the resected breast tumor specimen and axillary lymph nodes after neoadjuvant chemotherapy); R, retrospective; RCB, residual cancer burden (RCB ≤ 1 was defined as responders); RIA, radioimmunoassay.

a

Vitamin D as a continuous variable.

Figure 2

Risk of bias plot on pathological complete response (pCR).

Figure image at the original source: open the original paper. This file is not included in this text import.

Associations between vitamin D and NAC response

Among the included studies, three included stage I: III tumors and used pCR as the primary outcome to measure the pathological response to NAC. As shown in Fig. 3A, by conducting meta-analysis, we observed a significant association between pretreatment vitamin D deficiency and an increased odd of non-pCR (OR=1.50, 95% CI: 1.11 to 2.03, P=0.008). Of note, effect estimates reported by these three studies showed good consistency where no between-study heterogeneity was detected (I 2=0%). As for overall pathological response (Fig. 3B) with combined measures of pCR, RCB and MPG, five studies were included and the meta-analysis identified a significant association of vitamin D deficiency with inferior response to NAC (OR=1.33, 95% CI: 1.01 to 1.75, P=0.046).

Of note, we observed a moderate level of heterogeneity (I2=15%) for this outcome with a broader definition of response. Visual inspection of the contour-enhanced funnel plot (Supplemental Fig. 2A,B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) did not identify any evident asymmetry, and the Egger’s test did not find any significant small study effects or publication bias (pCR: P=0.104; overall pathological response: P=0.819).

Figure 3

A Forest plot of the effects of vitamin D deficiency on not achieving pathological complete response (pCR); B Forest plot of the effects of vitamin D deficiency on no overall pathological response; C Forest plot of the effects of vitamin D deficiency on event-free survival (EFS).

Figure image at the original source: open the original paper. This file is not included in this text import.

Four studies reported EFS in BC patients receiving NAC. As shown in the forest plot (Fig. 3C), with mild heterogeneity revealed (I 2=1%), BC patients with pretreatment vitamin D deficiency tended to experience inferior EFS, although the association was not statistically significant (HR=1.27, 95% CI: 0.92 to 1.75, P=0.139). The funnel plot for EFS (Supplemental Fig. 2C of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) was also deemed symmetrical, with an Egger’s test presenting no evidence of small study effects (P=0.585).

Subgroup and sensitivity analysis

We conducted a subgroup meta-analysis using a random-effects model based on different study characteristics, including molecular subtype (hormone receptor, HR), treatment regimen, patient ethnicity, and clinical tumor stage. Outside meta-analysis on studies including stages I: III patients where pCR was adopted as the primary outcome, we did not find any significant associations between vitamin D deficiency and response to NAC, although all the pooled estimates showed concordant directions of effect that indicated potential harmful roles of vitamin D deficiency on NAC response (vitamin D as a dichotomous variable, with forest plots presented in Fig. 4A: F).

Similar results were also found in terms of overall pathological response (vitamin D as a continuous variable, Supplemental Fig. 3 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556), as well as EFS (regimen, ethnicity, and tumor stage, Supplemental Fig. 4A: D of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Figure 4

Subgroup analysis on the overall pathological response (vitamin D as a dichotomous variable). A Subgroup plot with HR-positive; B Subgroup plot with HR negative; C Subgroup plot with Chemotherapy including trastuzumab; D Subgroup plot with Asian; E Subgroup plot with European; F subgroup plot with stages I: III; HR-positive: Either estrogen receptor (ER) or progesterone receptor (PR) is positive; HR negative: Both estrogen and progesterone receptors are negative.

Figure image at the original source: open the original paper. This file is not included in this text import.

We conducted sensitivity analysis on response to NAC (Supplemental Fig. 5A of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) and EFS (Supplemental Fig. 5B of Supplemental Digital Content 1, http://links.lww.com/JS9/D556) outcomes by including only studies with high methodological quality (NOS≥7), and the direction of effects remained consistent (response: OR=1.46, 95% CI: 0.85 to 2.52, P=0.170; EFS: OR=1.27, 95% CI: 0.92 to 1.75, P=0.139). In addition, two studies analyzed the association using vitamin D level of a continuous scale37,38, our meta-analysis failed to observe a significant association between lower vitamin D (per 1 unit) and response to NAC (OR=1.00, 95% CI: 0.99 to 1.01, P=0.924, Supplemental Fig. 6 of Supplemental Digital Content 1, http://links.lww.com/JS9/D556).

Discussion

Summary of main findings

To our best knowledge, this is the first systematic review and meta-analysis investigating the association between pretreatment vitamin D and response to NAC in BC patients. Our findings revealed a significant association of vitamin D deficiency with inferior response to NAC. Subgroup and sensitivity analysis found generally consistent evidence, though causality cannot be inferred from these observational data.

Comparison with existing literature and interpretation

Previous epidemiological evidence has robustly linked low circulating vitamin D level to escalated BC risk47Not reported49. In addition, vitamin D deficiency was more prevalent among patients with advanced stages and unfavorable clinicopathological characteristics, and could also influence overall survival for BC patients50,51. These findings were consistent with biological evidence underpinning the potential antitumor functions of vitamin D. Recent evidence has shed light upon the potential synergetic effect of vitamin D on chemotherapy drugs and its protective effect against chemotherapy side effects.

For example, vitamin D could intensify the combined effect of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) and paclitaxel on tumor growth and apoptosis in BC cells14. Also, studies showed that vitamin D supplementation provided protective effects against doxorubicin (DOX)-induced cardiotoxicity in BC patients52,53. Vitamin D insufficiency, on the other hand, was associated with chemotherapy-induced peripheral neuropathy from paclitaxel for early-stage BC18. Therefore, current biological evidence linked vitamin D level to response to NAC of BC and laid the foundation for our study to further investigate its predictive role in clinical practice.

Our meta-analysis provided the first population-level evidence supporting the linkage between pretreatment vitamin D deficiency and inferior response to NAC in BC patients. By pooling effect estimates, our study overcame the primary limitation of previous studies: insufficient statistical power from limited sample sizes: in the setting of NAC. We employed pCR as the primary outcome measuring pathological response to NAC given that it has been officially listed as a surrogate outcome by FDA and EMA24,25 for accelerated drug approval, and has been widely adopted as the primary outcome by many published trials.

Notably, two of the included studies37,41 utilized MPG or RCB criteria to evaluate tumor response, where formulas were applied to created scores to measure the residual tumor burden. These two studies included relatively small sample sizes and adding their estimates to our meta-analysis yielded a significant association between vitamin D deficiency and poor overall response, although an expected elevated moderate heterogeneity was observed for this secondary outcome. With a broader definition of treatment response using various criteria such as RCB and MPG, the pooled estimate still indicated a significant association between vitamin D deficiency and inferior response, which further strengthened the robustness of our findings.

We also noticed that these two studies reported point estimates of opposite direction, although the effects were nonsignificant. In addition to the different criteria used to define pathological response, they included BC patients with more advanced tumor stages (II: III), leading to possible lower response rates indicated by previous evidence40,42, and subsequently contributing to the heterogeneous effect estimates. The small sample sizes (<100) also yielded a greater extend of variability to their estimates, and their point estimates should be interpreted with caution.

EFS was also investigated as a secondary outcome in our study. Due to a limited number of outcome events, we failed to identify a significant impact of vitamin D on EFS, although a consistent direction of association was detected. Previous observational evidence had uncovered a favorable impact of vitamin D level on overall and disease-free survival for all BC patients54, and this was expected to be further validated among BC patients receiving NAC by conducting more prospective studies with larger sample sizes.

Another point worth mentioning was the dichotomized definition and arbitrary threshold selection of vitamin D deficiency. Although all the included studies chose a widely recommended threshold (<20 ng/ml), vitamin D levels and deficiency thresholds can vary depending on the assay used, geography, and population characteristics55,56. Moreover, epidemiological evidence demonstrated that dichotomy could lead to loss of information with subsequent impaired statistical power and possible biases57. Our systematic review only found two studies37,38 that reported the regression coefficients where vitamin D level was modeled in a continuous scale, and null effects were identified from the underpowered meta-analysis.

Future efforts were merited to explore the possible dose-response relationship between vitamin D level and response to NAC.

Of note, our extensive literature search identified no prospective studies yet on this topic, leading to all the included studies in our meta-analysis being retrospective in design, which introduced a risk of bias, particularly in patient selection and comparability, across different studies. Among the eligible studies, the primary source for risk of bias based on the NOS score was the lack of comparability, where crude ORs were used as effect estimates with covariates unadjusted. Consequently, one of the three studies with high risk (NOS<7)39,41,42 reported an reversed direction of effect41, although the result was not statistically significant.

To mitigate the risk of selection bias, the included high-quality (NOS≥7) studies enrolled patients from multiple centers, while adjusting for common covariates in multivariable analyses37,38,40. Based on that, we conducted sensitivity analysis by excluding studies with low NOS scores, and observed a consistent direction of effect, which further strengthened the robustness of our findings. However, due to the retrospective nature, our findings could provide initial evidence on the association between vitamin D and NAC response, and support a pressing need for prospective studies in the future to confirm this finding.

Anthracycline-based or taxane-based therapies are commonly prescribed in the current regimen of NAC58, which were also adopted by studies included in this meta-analysis. For human epidermal growth factor receptor 2 (HER-2) positive patients, trastuzumab would also be added. We conducted subgroup analysis based on treatment regimen and found the nonsignificant effect of vitamin D among studies including trastuzumab for HER-2 positive patients. However, due to data availability, we were unable to perform separate analysis on HER-2 positive patients, which merited future investigation in whether vitamin D was less predictive of response to targeted therapies as current biological evidence has been primarily focusing on chemotherapeutic agents.

Scientific evidence indicated that vitamin D intensified the effects of paclitaxel through down-regulated B-cell lymphoma-2 (Bcl-2) expression and upregulated the expression of Bcl-2 associated X (Bax) and cleaved caspase-3 in BC cells, thereby promoting the apoptosis of BC tumor cells14,17. With respect to other molecular subtypes, we conducted stratified analyses by hormone receptor (HR) status, but with only two studies eligible, we did not identify any significant effects of vitamin D among either HR+ or HR− patients. There has been evidence showing that lower vitamin D level was associated with unfavorable BC molecular subtypes, that is triple-negative tumors35,59.

Vitamin D might also influence the therapeutic effect in BC patients with certain molecular subtypes, such as estrogen receptor (ER) and HR-positive tumors60Not reported62. These findings pointed to a potential modifying effect of molecular subtypes on the association between vitamin D and treatment response. Owing to limited data, however, we were unable to assess possible effect modification by conducting subgroup analyses. More studies with granular subgroup data are warranted in the future to further clarify these effects.

Strengths and limitations of the study

We have performed, to our best knowledge, the first systematic review and meta-analysis on the association between pretreatment vitamin D and response to NAC in BC patients. However, there were several limitations that should be noted for current evidence. Firstly, although our meta-analysis has provided pooled effect estimates with much improved statistical power, relatively small sample sizes, especially for specific subgroups, could limit the credibility of our findings. Given the unavailable individual-level data, we were unable to adjust the possible confounders such as comorbidities and lifestyles (e.g. obesity and physical activity), which were associated with vitamin D level and could influence response to NAC.

Moreover, there has been a lack of data for patients of particular molecular subtypes such as triple-negative BC. Secondly, the retrospective nature of included studies incurred a risk of biases, and the observed association could not be interpreted as causality. Our study calls for more prospective studies with larger sample sizes to further validate the association. Thirdly, the included studies used the same threshold to dichotomize vitamin D, although the measured level could vary across diverse populations and different measuring techniques, which remained to be further investigated with more granular data accumulated in the future.

Fourthly, although the funnel plots and Egger’s test did not identify significant biases from small study effects, the statistical tests were underpowered due to the small number of included studies (n<10) and the results should be interpreted with caution. Finally, due to limited data, current evidence was unable to address the possible dose-response effect of vitamin D on NAC response. As such, future efforts are imperative to conduct large-scale prospective cohort studies with well-defined subgroups of various molecular subtypes to reassess this association.

Clinical implications and future directions

Vitamin D deficiency is highly prevalent worldwide and persists as a potential shared risk factor for many conditions including cancer, posing a major threat to human health63. BC patients are more susceptible to vitamin D deficiency in comparison to the general population64,65. Moreover, a significant decrease of the vitamin D level has been widely observed after the completion of NAC in BC patients66,67. Previous evidence has observed an adverse impact of lower plasma vitamin D level on survival outcomes of BC patients, on top of which our study provided further insights that vitamin D could potentially sensitize patients to NAC.

Our meta-analysis of retrospective cohorts calls for more prospective studies to investigate the potential causality between vitamin D and response to NAC. On the basis of a robust association, advanced approaches such as mendelian randomization could be performed to explore the potential causality between vitamin D level and clinical outcomes in BC patients, and randomized controlled trials (RCTs) that investigate the effects of vitamin D supplementation with varied doses and time schedules on improving response to NAC in BC patients are also expected in the future.

Also, as circulating vitamin D can be readily modified at a low cost, our findings highlighted the possibility of improving response to NAC for BC patients via vitamin D supplementation and laid the groundwork for future well-designed clinical investigations exploring varied doses of vitamin D supplementation for BC patients receiving NAC. Given the limited sample size of current studies68, whether intense pretreatment vitamin D supplementation could compensate for the adverse impact on response to NAC or whether it would be too late still needs to be verified by future population-based prospective studies.

Conclusion

Our study suggested an association between pretreatment vitamin D deficiency and reduced response to NAC in BC patients, although causality could not be inferred from current evidence with observational design. Therefore, active surveillance on vitamin D level as a biomarker before and during NAC were warranted for BC patients. However, as a safe intervention at a low cost, the causal effect of vitamin D supplementation to improve treatment response could only be proved by future RCTs. Also, our meta-analysis supports a compelling need for future prospective studies with larger sample sizes and well-designed subgroups to strengthen current evidence.

Ethical approval

Not applicable.

Consent

Not applicable.

Source of funding

This work was supported by the National Key Research and Development Program of China (grant no. 2023YFC3402100), the National Natural Science Foundation of China (grant no. 92259102 and 82103918), the Natural Science Foundation of Sichuan Province (grant no. 2024NSFSC0057 and 2025NSFSC0554).

Author contribution

Q.Y., C.S., J.H., X.X., H.L., X.W., X.C., Y.X., Y.Z., C.X., and Y.H.: acquisition, analysis, or interpretation of data; Q.Y., C.S., Y.H., and C.X.: drafting of manuscript; C.S. and X.X.: statistical analysis; Y.H. and C.X.: study supervision. All co-authors contributed in critical revision of the manuscript for important intellectual content.

Conflicts of interest disclosure

The authors declare no conflicts of interest.

Research registration unique identifying number (UIN)

  1. Name of the registry: International Prospective Register of Systematic Reviews (PROSPERO).

  2. Unique identifying registration number: CRD42024532891.

  3. Hyperlink to the registration: https://www.crd.york.ac.uk/prospero/#recordDetails.

Guarantor

Yazhou He.

Data availability statement

All data in this article can be shared upon reasonable request to the corresponding author.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Supplementary Material

SUPPLEMENTARY MATERIAL

Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.

Acknowledgements

Assistance with the study: None declared.

Presentation: None.

Chi Shu, Qian Yang, and Jun Huang contributed equally to this manuscript.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s website, www.lww.com/international-journal-of-surgery.

Published online 18 November 2024

References

1 Sung H Ferlay J Siegel RL . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin 2021 ;71 :209Not reported249 . 33538338 10.3322/caac.21660
2 van der Hage JH van de Velde CJH Mieog S . Preoperative chemotherapy for women with operable breast cancer . Cochrane Database Syst Rev 2007 ;2 :CD005002 . 10.1002/14651858.CD005002.pub2 PMC7388837 17443564
3 Wang H Mao X . Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer . Drug Des Devel Ther 2020 ;14 :2423Not reported2433 . 10.2147/DDDT.S253961 PMC7308147 32606609
4 Heil J Kuerer HM Pfob A . Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges . Ann Oncol 2020 ;31 :61Not reported71 . 31912797 10.1016/j.annonc.2019.10.012
5 Chiba A Raman R Thomas A . Serum vitamin D levels affect pathologic complete response in patients undergoing neoadjuvant systemic therapy for operable breast cancer . Clin Breast Cancer 2018 ;18 :144Not reported149 . 29290565 10.1016/j.clbc.2017.12.001 PMC6140343
6 van Mackelenbergh MT Seither F Möbus V . Effects of capecitabine as part of neo-/adjuvant chemotherapy: A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients . Eur J Cancer 2022 ;166 :185Not reported201 . 35305453 10.1016/j.ejca.2022.02.003
7 Harbeck N . Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer . Breast 2022 ;62 Suppl 1 (Suppl 1 ):S12Not reporteds16 . 35148934 10.1016/j.breast.2022.01.006 PMC9097807
8 Zhang J Wu Q Yin W . Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients . BMC Cancer 2023 ;23 :431 . 37173635 10.1186/s12885-023-10817-2 PMC10176880
9 Yao S Ambrosone CB . Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women . J Steroid Biochem Mol Biol 2013 ;136 :337Not reported341 . 22995734 10.1016/j.jsbmb.2012.09.010
10 Muñoz A Grant WB . Vitamin D and cancer: an historical overview of the epidemiology and mechanisms . Nutrients 2022 ;14 :1448 . 35406059 10.3390/nu14071448 PMC9003337
11 Agwa MM Abu-Serie MM Abdelmonsif DA . Vitamin D3/phospholipid complex decorated caseinate nanomicelles for targeted delivery of synergistic combination therapy in breast cancer . Int J Pharm 2021 ;607 :120965 . 34339814 10.1016/j.ijpharm.2021.120965
12 Veeresh PKM Basavaraju CG Dallavalasa S . Vitamin D3 inhibits the viability of breast cancer cells in vitro and ehrlich ascites carcinomas in mice by promoting apoptosis and cell cycle arrest and by impeding tumor angiogenesis . Cancers (Basel) 2023 ;15 :4833 . 37835527 10.3390/cancers15194833 PMC10571758
13 Wietrzyk J Nevozhay D Milczarek M . Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model . Cancer Chemother Pharmacol 2008 ;62 :787Not reported797 . 18188568 10.1007/s00280-007-0666-6
14 Liu X Lv H Shen H . Vitamin D enhances the sensitivity of breast cancer cells to the combination therapy of photodynamic therapy and paclitaxel . Tissue Cell 2022 ;77 :101815 . 35623307 10.1016/j.tice.2022.101815
15 Segovia-Mendoza M García-Quiroz J Díaz L . Combinations of calcitriol with anticancer treatments for breast cancer: an update . Int J Mol Sci 2021 ;22 :12741 . 34884550 10.3390/ijms222312741 PMC8657847
16 Tan KW Sampson A Osa-Andrews B . Calcitriol and calcipotriol modulate transport activity of ABC transporters and exhibit selective cytotoxicity in MRP1-overexpressing cells . Drug Metab Dispos 2018 ;46 :1856Not reported1866 . 30232176 10.1124/dmd.118.081612 PMC7333660
17 Attia YM El-Kersh DM Ammar RA . Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer . Chem Biol Interact 2020 ;315 :108865 . 31628941 10.1016/j.cbi.2019.108865
18 Chen CS Zirpoli G Barlow WE . Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in SWOG S0221 . J Natl Compr Canc Netw 2023 ;21 :1172Not reported1180 e3 . 37935109 10.6004/jnccn.2023.7062 PMC10976748
19 Page MJ McKenzie JE Bossuyt PM . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews . Int J Surg 2021 ;88 :105906 . 33789826 10.1016/j.ijsu.2021.105906
20 Shea BJ Reeves BC Wells G . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both . BMJ 2017 ;358 :j4008 . 28935701 10.1136/bmj.j4008 PMC5833365
21 Wells GA Shea B O’Connell D . Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
22 Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses . Eur J Epidemiol 2010 ;25 :603Not reported605 . 20652370 10.1007/s10654-010-9491-z
23 von Minckwitz G Untch M Blohmer JU . Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes . J Clin Oncol 2012 ;30 :1796Not reported1804 . 22508812 10.1200/JCO.2011.38.8595
24 Agency EM . Draft guideline on the role of the pathological complete response as an endpoint in neoadjuvant breast cancer studies. 2014. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165781.pdf
25 FDA . Services UDoHaH, Ad-ministration UFaD, (CDER) CfDEaR. Guidance for Industry: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf
26 Symmans WF Peintinger F Hatzis C . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy . J Clin Oncol 2007 ;25 :4414Not reported4422 . 17785706 10.1200/JCO.2007.10.6823
27 Ogston KN Miller ID Payne S . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival . Breast 2003 ;12 :320Not reported327 . 14659147 10.1016/s0960-9776(03)00106-1
28 Ross AC Manson JE Abrams SA . The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know . J Clin Endocrinol Metab 2011 ;96 :53Not reported58 . 21118827 10.1210/jc.2010-2704 PMC3046611
29 Higgins JP Thompson SG Deeks JJ . Measuring inconsistency in meta-analyses . BMJ 2003 ;327 :557Not reported560 . 12958120 10.1136/bmj.327.7414.557 PMC192859
30 Goorts B van Nijnatten TJ de Munck L . Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients . Breast Cancer Res Treat 2017 ;163 :83Not reported91 . 28205044 10.1007/s10549-017-4155-2 PMC5387027
31 Li Y Maimaitiaili A Qu F . Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study . Am J Cancer Res 2023 ;13 :3571Not reported3581 . 37693150 PMC10492098
32 Fasching PA Heusinger K Haeberle L . Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment . BMC Cancer 2011 ;11 :486 . 22081974 10.1186/1471-2407-11-486 PMC3262864
33 Sharma P Stecklein SR Yoder R . Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial . JAMA Oncol 2024 ;10 :227Not reported235 . 37991778 10.1001/jamaoncol.2023.5033 PMC10666040
34 Tichy JR Deal AM Anders CK . Race, response to chemotherapy, and outcome within clinical breast cancer subtypes . Breast Cancer Res Treat 2015 ;150 :667Not reported674 . 25814053 10.1007/s10549-015-3350-2 PMC4419268
35 Zemlin C Altmayer L Stuhlert C . Prevalence and relevance of vitamin D deficiency in newly diagnosed breast cancer patients: a pilot study . Nutrients 2023 ;15 :1450 . 36986179 10.3390/nu15061450 PMC10056197
36 Egger M Davey Smith G Schneider M . Bias in meta-analysis detected by a simple, graphical test . BMJ 1997 ;315 :629Not reported634 . 9310563 10.1136/bmj.315.7109.629 PMC2127453
37 Clark AS Chen J Kapoor S . Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657) . Cancer Med 2014 ;3 :693Not reported701 . 24719175 10.1002/cam4.235 PMC4101761
38 Charehbili A Hamdy NA Smit VT . Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: data from the NEOZOTAC trial (BOOG 10-01) . Breast 2016 ;25 :69Not reported74 . 26614548 10.1016/j.breast.2015.10.005
39 Kim JS Haule CC Kim JH . Association between changes in serum 25-hydroxyvitamin D Levels and survival in patients with breast cancer receiving neoadjuvant chemotherapy . J Breast Cancer 2018 ;21 :134Not reported141 . 29963108 10.4048/jbc.2018.21.2.134 PMC6015976
40 Viala M Chiba A Thezenas S . Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study . BMC Cancer 2018 ;18 :770 . 30060745 10.1186/s12885-018-4686-x PMC6066931
41 Atci M Cekin R . Predictive Importance of Vitamin D on response to neoadjuvant chemotherapy in turkish patients with locally advanced hormone receptor positive breast cancer . Eur J Med Investig 2021 ;5 :388Not reported393 .
42 Tokunaga E Masuda T Ijichi H . Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy . Breast Cancer 2022 ;29 :156Not reported163 . 34487328 10.1007/s12282-021-01292-3 PMC8732931
43 Arief N Hantoro I Iskandar A . Relationship of blood vitamin-D levels on neoadjuvant chemotherapy response of caf (tumor size based on ultrasonographic examination) in post menopause women with locally advance breast cancer in Dr. Soetomo General Hospital Surabaya . Ind J Publ Health Res Developm 2020 ;11 :203Not reported209 .
44 Meluch M Kowalska M Jagiello-Gruszfeld A . Effect of neutrophil-to-lymphocyte ratio and vitamin D3 levels on the pathological complete response after neoadjuvant treatment in TNBC and HER2-positive early breast cancer: results of a prospective study . Qeios 2023 ;1 1Not reported16 . doi: 10.32388/USPJ73
45 Çetin Ordu FA Özmen. V . Vitamin D can increase pathological response of the breast cancer patients treated with neoadjuvant therapy https://clinicaltrials.gov/study/NCT03986268
46 Douglas EH . Impact of vitamin D supplementation on the rate of pathologic complete response in vitamin D deficient patients https://clinicaltrials.gov/study/NCT04677816
47 Hossain S Beydoun MA Beydoun HA . Vitamin D and breast cancer: a systematic review and meta-analysis of observational studies . Clin Nutr ESPEN 2019 ;30 :170Not reported184 . 30904218 10.1016/j.clnesp.2018.12.085 PMC6570818
48 McNamara M Rosenberger KD . The significance of vitamin D status in breast cancer: a state of the science review . J Midwifery Womens Health 2019 ;64 :276Not reported288 . 30977263 10.1111/jmwh.12968
49 Visvanathan K Mondul AM Zeleniuch-Jacquotte A . Circulating vitamin D and breast cancer risk: an international pooling project of 17 cohorts . Eur J Epidemiol 2023 ;38 :11Not reported29 . 36593337 10.1007/s10654-022-00921-1 PMC10039648
50 Heiranizadeh N Alavizadeh FS Jafari Nodooshan J . Evaluation of the relationship between serum levels of 25-hydroxyvitamin D and prognostic factors in breast cancer . Pol Przegl Chir 2022 ;95 :1Not reported5 . 10.5604/01.3001.0015.9281 36805306
51 Yao S Kwan ML Ergas IJ . Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study . JAMA Oncol 2017 ;3 :351Not reported357 . 27832250 10.1001/jamaoncol.2016.4188 PMC5473032
52 El-Bassiouny NA Helmy MW Hassan MAE . The cardioprotective effect of vitamin D in breast cancer patients receiving adjuvant doxorubicin based chemotherapy . Clin Breast Cancer 2022 ;22 :359Not reported366 . 35241369 10.1016/j.clbc.2022.01.008
53 Lee KJ Wright G Bryant H . Cytoprotective effect of vitamin D on doxorubicin-induced cardiac toxicity in triple negative breast cancer . Int J Mol Sci 2021 ;22 :7439 . 34299059 10.3390/ijms22147439 PMC8305038
54 Li C Li H Zhong H . Association of 25-hydroxyvitamin D level with survival outcomes in female breast cancer patients: A meta-analysis . J Steroid Biochem Mol Biol 2021 ;212 :105947 . 34214604 10.1016/j.jsbmb.2021.105947
55 Ahmad SJ Ahmed AR Ali J . The correlation between vitamin D levels and demographics in patients with gastrointestinal disorders; a cross-sectional study . Gastroenterol Hepatol Bed Bench 2020 ;13 :223Not reported231 . 32821352 PMC7417489
56 Sowah D Fan X Dennett L . Vitamin D levels and deficiency with different occupations: a systematic review . BMC Public Health 2017 ;17 :519 . 28637448 10.1186/s12889-017-4436-z PMC5480134
57 Altman DG Royston P . The cost of dichotomising continuous variables . BMJ 2006 ;332 :1080 . 16675816 10.1136/bmj.332.7549.1080 PMC1458573
58 Pathak M Dwivedi SN Deo SVS . Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol . Syst Rev 2018 ;7 :89 . 29945652 10.1186/s13643-018-0754-1 PMC6020442
59 Abulkhair O Saadeddin A Makram O . Vitamin D levels and breast cancer characteristics: findings in patients from Saudi Arabia . J Steroid Biochem Mol Biol 2016 ;164 :106Not reported109 . 26554935 10.1016/j.jsbmb.2015.11.003
60 Dizdar O Bulut N Altundag K . Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer . Breast 2008 ;17 :120 . 18037293 10.1016/j.breast.2007.10.013
61 Dizdar O Bulut N Altundag K . Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer . Breast Cancer Res Treat 2008 ;109 :403 . 17624607 10.1007/s10549-007-9647-z
62 Krishnan AV Swami S Feldman D . The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer . Steroids 2012 ;77 :1107Not reported1112 . 22801352 10.1016/j.steroids.2012.06.005 PMC3429709
63 Zhu K Knuiman M Divitini M . Lower serum 25-hydroxyvitamin D is associated with colorectal and breast cancer, but not overall cancer risk: a 20-year cohort study . Nutr Res 2019 ;67 :100Not reported107 . 30982554 10.1016/j.nutres.2019.03.010
64 Fassio A Porciello G Carioli G . Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy . Reumatismo 2024 ;76 :21Not reported34 . 10.4081/reumatismo.2024.1632 38523582
65 Voutsadakis IA . Vitamin D baseline levels at diagnosis of breast cancer: a systematic review and meta-analysis . Hematol Oncol Stem Cell Ther 2021 ;14 :16Not reported26 . 33002425 10.1016/j.hemonc.2020.08.005
66 Kim HJ Koh BS Yu JH . Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients . Eur J Cancer 2014 ;50 :1403Not reported1411 . 24703104 10.1016/j.ejca.2014.02.026
67 Jacot W Pouderoux S Thezenas S . Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy . Breast Cancer Res Treat 2012 ;134 :709Not reported717 . 22562178 10.1007/s10549-012-2084-7
68 Tirgar A Rezaei M Ehsani M . Exploring the synergistic effects of vitamin D and synbiotics on cytokines profile, and treatment response in breast cancer: a pilot randomized clinical trial . Sci Rep 2024 ;14 :21372 . 39266591 10.1038/s41598-024-72172-x PMC11393349
Publication and source details

Original title: Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies

Chi Shu; Qian Yang; Jun Huang; Xuan Xie; Hong Li; Hong Wu; Xin Wang; Xin Chen; Yuping Xie; Yanhong Zhou; Yazhou He; Chuan Xu

International Journal of Surgery (London, England) · 2024

* Corresponding author. Address: Department of Oncology and Department of Epidemiology and Medical Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China. Tel.: +86 288 550 1630. E-mail: yazhou.he@scu.edu.cn (Y. He); Department of Oncology and Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China. Tel.: +86 288 739 4677. E-mail: xuchuan100@uestc.edu.cn (C. Xu).Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.2024https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:11:04.276242+00:00

DOI: 10.1097/js9.0000000000002142 · PMC11634150